MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Clinical trials for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to free blood cancer patients from transfusions
Disease control Recruiting nowThis study is testing an experimental drug called DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who have anemia. The main goals are to see if the drug is safe and if it can help improve red blood cell counts, potentially reducing or eliminating the need for b…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for blood cancer patients who need better treatment
Disease control Recruiting nowThis early-stage study is testing whether adding the drug abemaciclib to the standard treatment ruxolitinib is safe and more effective for people with myelofibrosis, a serious bone marrow cancer. The trial is for patients who are already taking ruxolitinib but still have signific…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…
Matched conditions: MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Apr 01, 2026 23:26 UTC